News Image

What's going on in today's after hours session

By Mill Chart

Last update: Nov 23, 2022

The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.

Today's after hours gainers

TickerChangeComment
TNYA14.75%TENAYA THERAPEUTICS INC's (NASDAQ:TNYA) shares rose 14.75% to $2.8. In the last 3 months the share price dropped with 44.67%.
REVB9.52%REVELATION BIOSCIENCES INC's (NASDAQ:REVB) stock price increased by 9.52% to $0.23. Shareholders saw the stock price going 34.02% lower in the past month.
AEI8.64%ALSET INC (NASDAQ:AEI) rose 8.64% to $0.24 during Wednesday's after hours session. This is a continuation of today's gain of 10.83%. NASDAQ:AEI released their earnings today.
HGEN7.14%HUMANIGEN INC's (NASDAQ:HGEN) shares rose 7.14% to $0.15. In the last 3 months the stock lost 48.77%.
EQRX4.87%EQRX INC's (NASDAQ:EQRX) shares rose 4.87% to $3.66. In the last month the stock lost 32.76%.
RKLB4.77%ROCKET LAB USA INC's (NASDAQ:RKLB) shares rose 4.77% to $4.61 during Wednesday's after hours session. Earlier today the company had a press release: NASA Selects Rocket Lab to Launch TROPICS Mission.
BSGM4.77%BIOSIG TECHNOLOGIES INC's (NASDAQ:BSGM) shares rose 4.77% to $0.4 during Wednesday's after hours session. The stock is trading 23.69% lower than a month ago.
BTCM4.76%BIT MINING LTD - SPON ADR's (NYSE:BTCM) shares rose 4.76% to $0.22. In the last 3 months the stock lost 46.75%.
NEXI4.55%NEXIMMUNE INC's (NASDAQ:NEXI) stock price is advancing with 4.55% to a price of $0.46. In the last month the stock lost 31.39%.
EDIT4.53%EDITAS MEDICINE INC's (NASDAQ:EDIT) shares rose 4.53% to $10.84 during Wednesday's after hours session. In the last 3 months the stock lost 30.07%.

For the full after hours gainers list go to our after hours gainers screener.

Today's after hours losers

TickerChangeComment
COSM-13.12%COSMOS HOLDINGS INC's (NASDAQ:COSM) shares fell 13.12% to $0.28. The company released earnings today. In the last month the stock gained 187.0%.
LU-6.86%LUFAX HOLDING LTD-ADR's (NYSE:LU) stock price is declining with 6.86% to a price of $1.63. LUFAX HOLDING LTD-ADR released earnings Yesterday. Shareholders saw the stock price going 59.95% lower in the past 3 months.
CNEY-6.21%CN ENERGY GROUP INC-A's (NASDAQ:CNEY) shares fell 6.21% to $1.66. The stock is trading 25.63% lower than 6 months ago.
GAU-5.0%GALIANO GOLD INC's (NYSEARCA:GAU) shares fell 5.0% to $0.57. In the last 3 months the stock gained 22.25%.
GROY-4.88%GOLD ROYALTY CORP's (NYSEARCA:GROY) shares fell 4.88% to $2.73 during Wednesday's after hours session. In the last year the stock lost 43.73%.
JFU-4.76%9F INC - ADR's (NASDAQ:JFU) stock price is declining with 4.76% to a price of $0.2. After today's gain of 10.53%, it goes down with 4.76% in today's after hours session.
CYBN-4.65%CYBIN INC's (NYSEARCA:CYBN) shares fell 4.65% to $0.41 during Wednesday's after hours session. The stock is trading 57.43% lower than 3 months ago.
VZIO-4.13%VIZIO HOLDING CORP-A's (NYSE:VZIO) shares fell 4.13% to $10.22. Two days ago the company had a press release: CORRECTING and REPLACING VIZIO Black Friday Deals: Celebrate Holiday Savings on Award-Winning TVs and Sound Bars.
KAL-4.04%KALERA PLC's (NASDAQ:KAL) stock price is declining with 4.04% to a price of $0.15. After running up 76.92% in today's session, NASDAQ:KAL is pulling back after hours.
SENS-3.44%SENSEONICS HOLDINGS INC's (NYSEARCA:SENS) shares fell 3.44% to $1.12. The stock is trading 35.2% lower than 3 months ago.

Our after hours losers screener will show you the full list.

Back

EDITAS MEDICINE INC

NASDAQ:EDIT (5/17/2024, 7:00:01 PM)

After market: 5.7592 +0.14 (+2.48%)

5.62

-0.27 (-4.58%)

EDIT News

News Image4 days ago - Editas Medicine, Inc.Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
News Image4 days ago - Editas Medicine, Inc.Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that...

News Image9 days ago - Editas Medicine, Inc.Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
News Image9 days ago - Editas Medicine, Inc.Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support...

News Image9 days ago - The Motley Fool1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?

The company has great potential if and when it enters the commercial stage.

News Image10 days ago - Market News VideoEditas Medicine Enters Oversold Territory (EDIT)
News Image10 days ago - InvestorPlaceEDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024

EDIT stock results show that Editas Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image11 days ago - Editas Medicine, Inc.Editas Medicine Announces First Quarter 2024 Results and Business Updates
News Image17 days ago - Editas Medicine, Inc.Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
News Image17 days ago - Editas Medicine, Inc.Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it...

News Image18 days ago - Editas Medicine, Inc.Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases

News Image18 days ago - Editas Medicine, Inc.Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases...

EDIT Links
Follow us for more